Head to Head Analysis: Spark Therapeutics (ONCE) vs. Its Competitors
Spark Therapeutics (NASDAQ: ONCE) is one of 288 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Spark Therapeutics to related businesses based on the strength of its risk, valuation, profitability, earnings, analyst recommendations, dividends and institutional ownership.
Insider and Institutional Ownership
91.0% of Spark Therapeutics shares are owned by institutional investors. Comparatively, 51.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 7.3% of Spark Therapeutics shares are owned by company insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Spark Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Spark Therapeutics Competitors||-4,766.74%||-354.83%||-43.39%|
Risk and Volatility
Spark Therapeutics has a beta of 3.38, suggesting that its share price is 238% more volatile than the S&P 500. Comparatively, Spark Therapeutics’ rivals have a beta of 6.57, suggesting that their average share price is 557% more volatile than the S&P 500.
Valuation & Earnings
This table compares Spark Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Spark Therapeutics||$20.36 million||-$165.64 million||-12.81|
|Spark Therapeutics Competitors||$464.68 million||$167.54 million||-6.57|
Spark Therapeutics’ rivals have higher revenue and earnings than Spark Therapeutics. Spark Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current ratings for Spark Therapeutics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Spark Therapeutics Competitors||1377||4466||12277||311||2.63|
Spark Therapeutics currently has a consensus target price of $87.23, suggesting a potential upside of 6.53%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 34.72%. Given Spark Therapeutics’ rivals higher probable upside, analysts clearly believe Spark Therapeutics has less favorable growth aspects than its rivals.
Spark Therapeutics rivals beat Spark Therapeutics on 7 of the 12 factors compared.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.